Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma
A. Marchetto, S. Ohmura, M. F. Orth, J. Li, F. S. Wehweck, M. M. L. Knott, S. Stein, D. Saucier, C. Arrigoni, J. S. Gerke, M. C. Baldauf, J. Musa, M. Dallmayer, T. L. B. Hoelting, M. Moretti, , T. G. P. Grunewald
The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.
bioRxiv · Mar 14, 2019Cancer Biology